These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1891 related articles for article (PubMed ID: 27540992)

  • 1. Targeting natural killer cells in cancer immunotherapy.
    Guillerey C; Huntington ND; Smyth MJ
    Nat Immunol; 2016 Aug; 17(9):1025-36. PubMed ID: 27540992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy.
    Michen S; Temme A
    Crit Rev Immunol; 2016; 36(4):329-347. PubMed ID: 28322137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy.
    Töpfer K; Cartellieri M; Michen S; Wiedemuth R; Müller N; Lindemann D; Bachmann M; Füssel M; Schackert G; Temme A
    J Immunol; 2015 Apr; 194(7):3201-12. PubMed ID: 25740942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tricking the balance: NK cells in anti-cancer immunity.
    Pahl J; Cerwenka A
    Immunobiology; 2017 Jan; 222(1):11-20. PubMed ID: 26264743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical applications of adoptive natural killer cell immunotherapy for cancer: current status and future prospects.
    Guo H; Qian X
    Onkologie; 2010; 33(7):389-95. PubMed ID: 20631487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tailoring Natural Killer cell immunotherapy to the tumour microenvironment.
    Barrow AD; Colonna M
    Semin Immunol; 2017 Jun; 31():30-36. PubMed ID: 28935344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
    Lin C; Zhang J
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.
    Smits NC; Coupet TA; Godbersen C; Sentman CL
    Expert Opin Biol Ther; 2016 Sep; 16(9):1105-12. PubMed ID: 27248342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR-NK Cells: From Natural Basis to Design for Kill.
    Khawar MB; Sun H
    Front Immunol; 2021; 12():707542. PubMed ID: 34970253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial: Molecular Strategies Aimed to Boost NK Cell-Based Immunotherapy of Cancer.
    Cifaldi L; Di Santo J; Olive D
    Front Immunol; 2020; 11():1132. PubMed ID: 32612604
    [No Abstract]   [Full Text] [Related]  

  • 11. Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective.
    Cifaldi L; Locatelli F; Marasco E; Moretta L; Pistoia V
    Trends Mol Med; 2017 Dec; 23(12):1156-1175. PubMed ID: 29133133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NK cells to cure cancer.
    Di Vito C; Mikulak J; Zaghi E; Pesce S; Marcenaro E; Mavilio D
    Semin Immunol; 2019 Feb; 41():101272. PubMed ID: 31085114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
    Davis ZB; Vallera DA; Miller JS; Felices M
    Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy.
    Alfarra H; Weir J; Grieve S; Reiman T
    Front Immunol; 2020; 11():575609. PubMed ID: 33304346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human NK cells: From surface receptors to clinical applications.
    Moretta L; Pietra G; Vacca P; Pende D; Moretta F; Bertaina A; Mingari MC; Locatelli F; Moretta A
    Immunol Lett; 2016 Oct; 178():15-9. PubMed ID: 27185471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.
    Gaggero S; Witt K; Carlsten M; Mitra S
    Front Immunol; 2020; 11():621225. PubMed ID: 33584718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?
    Ben-Shmuel A; Biber G; Barda-Saad M
    Front Immunol; 2020; 11():275. PubMed ID: 32153582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer.
    Arina A; Murillo O; Dubrot J; Azpilikueta A; Alfaro C; Pérez-Gracia JL; Bendandi M; Palencia B; Hervás-Stubbs S; Melero I
    Expert Opin Biol Ther; 2007 May; 7(5):599-615. PubMed ID: 17477799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive transfer of osteoclast-expanded natural killer cells for immunotherapy targeting cancer stem-like cells in humanized mice.
    Kozlowska AK; Kaur K; Topchyan P; Jewett A
    Cancer Immunol Immunother; 2016 Jul; 65(7):835-45. PubMed ID: 27034236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.
    Matosevic S
    J Immunol Res; 2018; 2018():4054815. PubMed ID: 30306093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 95.